StockNews.AI
LLY
Barrons
27 days

Lilly, Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. - Barron's

1. LLY and NVO dominate the U.S. weight-loss drug market. 2. Morningstar predicts a $200 billion market by 2031 for weight-loss drugs. 3. Goldman Sachs lowered its market estimate to $95 billion by 2030. 4. Several competitors are emerging in the weight-loss drug sector. 5. Amgen's MariTide shows promise but faces dropouts due to side effects.

6m saved
Insight
Article

FAQ

Why Bullish?

LLY maintains a strong position in a growing market dominated by them and Novo. Historical stability in leading drug sectors suggests price resilience.

How important is it?

The competitive landscape in weight-loss drugs affects LLY's market positioning and future revenues.

Why Long Term?

Market growth expectations are based on long-term trends, emergent competitors could influence in the coming years.

Related Companies

NVOAMGNVKTXZEALAZN

Related News